InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,817.65
(
0.04%
)
Post# of 23979
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

buckiii2

Send PM Follow Ignore
Followers 59
Posts 4696
Boards Moderated 0
Alias Born 04/27/2009

buckiii2

Re: buckiii2 post# 23837

Friday, 11/10/2017 11:32:27 AM

Friday, November 10, 2017 11:32:27 AM

Post# of 23979
ONCS. H.C. Wainwright's Ram Selvaraju anticipates ONCS could apply with Phase IIb data for Breakthrough Therapy designation.

Julie Lamb, Senior Editor-November 10, 2017, 10:24 AM EDT

https://www.smarteranalyst.com/2017/11/10/heres-bull-sees-next-oncosec-medical-inc-oncs-back-phase-ii-combination-trial-success/
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up